Though, this was not applied to patients with high expression of TET2. This difference in the results could be attributed to the impact of using unsorted bone marrow cells other than using blast cells, in addition to that some patients included in the current study had AML with cytogenetic abnormalities. The gene discussed is TET2; the disease is acute myeloid leukemia.